The Medical Advisor

Executive Summary Cancer is no longer best understood purely as a genetic disease. By 2026, a growing body of research supports a more integrated model: cancer as a metabolic, immunologic, and microenvironmental disorder . This report presents a unified framework: Cancer is a dysregulated adaptive system driven by metabolic flexibility, immune evasion, and microenvironmental control. Key insights: Tumors rely on three dominant fuels : glucose, glutamine, and lactate Mitochondrial dysfunction is central to cancer progression and stemness The tumor microenvironment (TME) actively suppresses immune response Metabolic therapies may enhance—not replace—standard treatments Combination strategies outperform single-agent approaches. Introduction: A Broader View of Cancer Biology Traditional oncology often focuses on genetic mutations and targeted therapies. While mutations are critical, emerging research shows that cancer is also a disease of metabolic dysfunction and immu...

Introduction: The Rise of Metabolic Therapy in Cancer Care The field of oncology is generally based on three treatment areas: medical oncology, radiation oncology, and surgical oncology. However, another area is looming on the horizon, quickly gaining traction as a new and exciting frontier of cancer treatment. Metabolic oncology, also known as cancer metabolism, focuses on how cancer cells use energy and nutrients differently than normal cells. Scientists working in metabolic oncology look for targets in these metabolic processes to create treatments that can specifically attack cancer cells while protecting healthy cells. A  2026 large-scale population study  published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity — it may be a centra...